NCT01223235

Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
Sponsors: Memorial Sloan-Kettering Cancer Center, Genentech
Phase n/a 

NCT01141491

Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free

Conditions: Sarcoma
Sponsors: MabVax Therapeutics, Inc.
Phase II

NCT00911560

Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral ß-glucan for High-Risk Neuroblastoma

Conditions: Neuroblastoma
Sponsors: Memorial Sloan-Kettering Cancer Center
Phase I/II

NCT00857545

OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Sponsors: Gynecologic Oncology Group, National Cancer Institute (NCI)
Phase II

NCT00693342

Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Sponsors: Gynecologic Oncology Group, National Cancer Institute (NCI)
Phase III

NCT00597272

Determine Toxicity and Antibody Responses With a KLH Conjugated Bivalent Vaccine Containing GD2 Lactone, GD3 Lactone With Immunological Adjuvant QS-DG or OPT-821 in Patients With Disease Free AJCC Stage III or IV Cutaneous Melanoma

Conditions: Melanoma
Sponsors: Memorial Sloan-Kettering Cancer Center
Phase n/a